Safety and Health at Work

Occupational Safety and Health Research Institute, Korea Occupational Safety and Health Agency (산업안전보건연구원)
권호 표지
DOI QR코드

DOI QR Code

Follow-up of Soluble Mesothelin-Related Protein Levels in Participants With Asbestos-Related Disorders

  • Park, Eun-Kee (Department of Medical Humanities and Social Medicine, College of Medicine, Kosin University) ;
  • Johnson, Anthony R. (Department of Respiratory Medicine, Liverpool Hospital) ;
  • Wilson, Donald (Department of Public Health and Primary Care, College of Medicine, Nursing and Health Sciences, Fiji National University) ;
  • Thomas, Paul S. (School of Medical Sciences, Faculty of Medicine, University of New South Wales) ;
  • Yates, Deborah H. (Department of Thoracic Medicine, St Vincent's Hospital)
  • Received : 2020.03.02
  • Accepted : 2020.07.27
  • Published : 2020.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Asbestos exposure is associated with the development of the cancer malignant mesothelioma (MM). Measurement of soluble mesothelin-related protein (SMRP) has been suggested as a method for detection of MM in its early stages. We prospectively examined SMRP levels in participants with asbestos exposure who are a group at a high risk of development of MM. Methods: This study was a follow-up of our cohort of 322 asbestos-exposed participants. No further participants developed MM or malignancy over the study period. Mean follow-up time was 22.9 months. Results: Mean (standard deviation) SMRP levels at baseline and follow-up were 0.94 (0.79) and 0.91 (0.86) nmol/L (p = 0.1033), respectively. Mean SMRP levels of the healthy individuals exposed to asbestos at baseline was significantly lower than those of participants with asbestosis and pleural plaques alone; similar patterns were found on follow-up measurements. There was a statistically significant effect of age on serial SMRP measurements. Our study confirms higher levels in participants with nonmalignant asbestos-related disorders. Levels decreased in asbestos-related disorders other than asbestosis, where a small increase was observed. We did not detect any further cases of malignancy. Conclusion: Monitoring programs for early detection of MM need to take into account increased SMRP levels found in benign asbestos-related diseases.

Keywords

Acknowledgement

The authors are grateful to all participants whose participation enabled us to complete the study. This study was partially funded by the Workers' Compensation (Dust Diseases) Board of NSW, Australia.

References

  1. Reid A, Heyworth J, de Klerk NH, Musk B. Cancer incidence among women and girls environmentally and occupationally exposed to blue asbestos at Wittenoom, Western Australia. Int J Canc 2008;122:2337-44.
  2. Mirabelli D, Cavone D, Merler E, Gennaro V, Romanelli A, Mensi C, et al. Nonoccupational exposure to asbestos and malignant mesothelioma in the Italian National Registry of Mesotheliomas. Occup Environ Med 2010;67:792-4.
  3. Driscoll T, Rushton L, Steenland K, Hutchings S, Straif K, Abate D, et al. Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016. Occup Environ Med 2020;77:151-9.
  4. Le GV, Takahashi K, Karjalainen A, Delgermaa V, Hoshuyama T, Miyamura Y, et al. National use of asbestos in relation to economic development. Environ Health Perspect 2010;118:116-9.
  5. Mesothelioma in Australia. Australian Institute of Health and Welfare. 2017. 2017 [cited 2020 Feb 1]. Available from: https://www.aihw.gov.au/reports/cancer/mesothelioma-in-australia-2017/data.
  6. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
  7. Musk AW, Olsen N, Alfonso H, Reid A, Mina R, Franklin P, et al. Predicting survival in malignant mesothelioma. Eur Respir J 2011;38:1420-4.
  8. Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Canc Prevent 1997;6:162-6.
  9. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Canc 2005;92:587-93.
  10. Hyland RA, Ware S, Johnson AR, Yates DH. Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. Scand J Work Environ Health 2007;33:286-92.
  11. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008;3:851-7.
  12. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012;367:1417-27.
  13. Bayram M, Dongel I, Akbas, A, Benli I, Akkoyunlu ME, Bakan ND. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. Lung 2014;192:197-203.
  14. Demir M, Kaya H, Taylan M, Ekinci A, Yilmaz S, Teke F, et al. Evaluation of new biomarkers in the prediction of malignant mesothelioma in subjects with environmental asbestos exposure. Lung 2016;194:409-17.
  15. Johnen G, Burek K, Raiko I, Wichert K, Pesch B, Weber DG, et al. Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers. Sci Rep 2018;8:14321.
  16. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
  17. Scherpereel A, Grigorlu B, Conti M, Gey T, Gregoire M, Copin MC, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-60.
  18. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, et al. Mesomark: a potential test for malignant pleural mesothelioma. Clin Chem 2007;53:666-72.
  19. Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelin-related peptides concentrations in patients with malignant mesothelioma. Dis Markers 2012;32:123-31.
  20. Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ. Diagnostic values of soluble mesothelinrelated peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open 2014;4:e004145.
  21. Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, et al. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol 2011;85:185-92.
  22. Filiberti R, Marroni P, Spigno F, Merlo DF, Mortara V, Caruso P, et al. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos. Oncology 2014;86:33-43.
  23. Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, et al. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 2009;179:950-4.
  24. Hollevoet K, Van Cleemput J, Thimpont J, De Vuyst P, Bosquee L, Nackaerts K, et al. Serial measurements of mesothelioma serum biomarkers in asbestosexposed individuals: a prospective longitudinal cohort study. J Thorac Oncol 2011;6:889-95.
  25. Felten MK, Khatab K, Knoll L, Schettgen T, Muller-Berndorff H, Kraus T. Changes of mesothelin and osteopontin concentrations over time in formerly asbestos-exposed power industry workers. Int Arch Occup Environ Health 2014;87:195-204.
  26. Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008;178:832-7.
  27. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-73.
  28. Park EK, Yates DH, Creaney J, Thomas PS, Robinson BW, Johnson AR. Association of biomarker levels with severity of asbestos-related diseases. SHAW 2012;3:17-21.
  29. de Perrot M, Feld R, Leighl NB, Perentes JY, McKee TD, Donahoe L, et al. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2016;151:468-73.
  30. Understanding Mesothelioma: a guide for people with cancer, their families and friends. Cancer Council Australia. 2017 [cited 2020 Feb 1]. Available from: http://www.cancer.org.au/about-cancer/types-of-cancer/mesothelioma.html.
  31. Chen Z, Gaudino G, Pass HI, Carbone M, Yang H. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. Transl Lung Canc Res 2017;6:259-69.
  32. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2017;62:569-76.
  33. Creaney J, Musk AW, Robinson BW. Sensitivity of urinary mesothelin in patients with malignant mesothelioma. J Thorac Oncol 2010;5:1461-6.
  34. Aguilar-Madrid G, Pesch B, Calderon-Aranda ES, Burek K, Jimenez-Ramirez C, Juarez-Perez CA, et al. Biomarkers for predicting malignant pleural mesothelioma in a Mexican population. Int J Med Sci 2018;15:883-91.